Virginia localities are preparing to move into phase 1C as more vaccines become available to more of the population. One of ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY™ (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the ...